Spotlight Growth
No Result
View All Result
Monday, July 4, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Consumer Goods

The Beauty Health Company (NASDAQ: SKIN) Reports Strong Revenue Growth For Q4 and Fiscal Year 2021 Results

by admin
February 23, 2022
in Consumer Goods, Earnings
0
The Beauty Health Company NASDAQ SKIN Fiscal 2021 Results Spotlight Growth

The Beauty Health Company NASDAQ SKIN Fiscal 2021 Results Spotlight Growth

The Beauty Health Company (NASDAQ: SKIN) is a global beauty and health company, which primarily relies on its flagship brand, HydraFacial, a skin product developed using a patented Vortex-Fusion Delivery System to clean, exfoliate, extract, and hydrate skin. HydraFacial is available in more than 90 counties.

Shares of the skin care company are soaring 31% through early trading on Wednesday, February 23, 2022. Over the past three months, The Beauty Health Company has seen average daily volume of around 2.16 million shares. However, volume of 3.73 million shares or dollar volume of around $63.6 million, has already exchanged hands through early trading Wednesday.

The global skin care company is seeing shares rally after the company reported record fourth quarter and fiscal year 2021 financial results. For the fiscal year 2021, The Beauty Health Company reported net sales growth of 118.3% to $260.1 million. Adjusted EBITDA came in at $32.7 million, an increase of 12.6% compared to 2020.

During the fourth quarter, the company reported net sales of $77.9 million, which represents year-over-year growth of 105.6%. Gross margins improved to 72.9% compared to 67.8% last year. The Beauty Health Company did report a net loss of $17.3 million, compared to a loss of $7.5 million during the fourth quarter of 2022.

Management issued strong fiscal 2022 guidance, which predicts another year of record growth ahead. Fiscal 2022 net sales are estimated to come in somewhere between $320 million and $330 million. Adjusted EBITDA estimates reach $50 million for the current fiscal year.

“We are extremely pleased with our accomplishments this quarter and for the full year 2021, exceeding our guidance. Importantly, we navigated through macro challenges and COVID, delivering strong results by executing against our key strategic initiatives. Our performance is proof of the compelling opportunity we have to capture the convergence of medical aesthetics and skincare,” said Brent Saunders, Beauty Health’s Executive Chairman.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: Beauty Health Companybeauty productsbeauty stockscommon stockconsumer goodsconsumer stocksconsumerscosmeticsday tradingearningsemerging growthHydraFacialinvestinginvesting newsinvestmentmanufacturingmicrocap stocksNASDAQnewspublic companyRobinhoodrobinhood stockssalesservicesskinskin careSKIN stocksmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatment
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022
Ayurcann CSE AYUR OTCQB AYURF July Product Rollout Canada Spotlight Growth

Ayurcann (CSE: AYUR) (OTCQB: AYURF) Prepares for July New Product Rollout as Distribution Expansion Continues Across Canada

June 27, 2022
NeuroSense Therapeutics NASDAQ NRSN Stage III ALS Biomarker Study Spotlight Growth

NeuroSense Therapeutics (NASDAQ: NRSN) Details PrimeC’s Positive Results from Stage III ALS Biomarker Study

June 27, 2022

Recent News

Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested